Physician profile
Christopher L Blanton
NPI 1336142892
$339,610.92
in general payments reported to CMS, 2019-2025
16 companies · $38K in 2025
The $38K reported for 2025 was more than what 98% of Ophthalmology providers received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $82K · 2020: $38K · 2021: $59K · 2022: $41K · 2023: $44K · 2024: $38K · 2025: $38K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $118K · Food and Beverage: $1,750.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $117,579.87 |
| Food and Beverage | $1,749.81 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Johnson & Johnson Surgical Vision, INC. | $331,837.68 | 2019-2025 | Star S4 Ir, Ifs Advanced Femtosec Laser, Elita |
| Eyevance Pharmaceuticals LLC | $6,287.89 | 2019-2022 | |
| Sun Pharmaceutical Industries INC. | $653.64 | 2019-2025 | Cequa, Bromsite, Xelpros |
| Nova Eye, INC. | $149.17 | 2023 | |
| Alcon Vision LLC | $125.92 | 2019-2023 | Rocklatan |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $125.84 | 2019-2020 | |
| Rxsight INC | $99.51 | 2024 | Rxsight Injector Cartridge, Rxsight Contact Lens, Light Adjustable Lens (Lal) |
| Glaukos Corporation | $91.03 | 2019-2022 | |
| Kala Pharmaceuticals, INC. | $54.90 | 2019-2020 | |
| Dompe US, INC. | $46.00 | 2025 | Oxervate |
| Tarsus Pharmaceuticals, INC. | $42.85 | 2025 | Xdemvy |
| Oyster Point Pharma, INC. | $32.05 | 2025 | Tyrvaya |
| Allergan, INC. | $20.34 | 2019 | |
| Carl Zeiss Meditec Ag | $19.40 | 2020 | |
| Carl Zeiss Meditec USA, INC. | $13.22 | 2021 |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sight Sciences, INC. | $11.48 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Christopher Blanton listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.